<DOC>
	<DOCNO>NCT01302938</DOCNO>
	<brief_summary>To compare effect tolterodine ER 4 mg placebo patient report outcomes subject overactive bladder 1 , 4 , 12 week treatment use innovative web-based trial design</brief_summary>
	<brief_title>Web-based Methodology Trial Evaluate Efficacy Safety Tolterodine ER Subjects With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>Female 21 year older Overactive bladder symptom ( subjectreported ) least 3 month Be resident United States America access able use computer internet access throughout duration study Clinically significant hepatic , renal neurological condition stroke ( residual deficit ) , multiple sclerosis , spinal cord injury , Parkinson 's disease . History cystitis , continence , urogenitalcancer radiation Subjects pregnant , nursing , positive urine pregnancy test intend become pregnant within 28 day completion trial .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Double-blind</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>frequency</keyword>
	<keyword>urgency</keyword>
	<keyword>web-based</keyword>
	<keyword>incontinence</keyword>
	<keyword>methodology</keyword>
	<keyword>ediary</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>tolerability ER</keyword>
	<keyword>overactive bladder</keyword>
</DOC>